This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Was MENTOR the final word for Rituximab in Membranous Nephropathy? Not so. We discuss STARMEN this week which compared sequential tacrolimus- rituximab with the Ponticelli protocol.
Steroids are the mainstay of minimal change. Or are they? Lets explore an RCT that bravely challenges the status quo of steroids with tacrolimus monotherapy